This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
A year after the FDA blessed Roche and Novartis’ Xolair (omalizumab) as the firs...
Beginning in late May, BMS will lay off 223 workers in Lawrenceville, New Jersey...
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has ...
Beginning in late May, BMS will lay off 223 workers in Lawrenceville, New Jersey...
Dr. Buzón discusses bridging science and reality, highlighting the vital role of...
Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak ...
During a quarterly conference call, as Apellis Pharmaceuticals discussed its pla...
Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak ...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
Rare Disease Day 2025 triggered a flurry of pharma marketing activity, with Arro...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
Europe's Committee for Medicinal Products for Human Use recommended four new dru...
Eisai plans to lay off 121 employees in the U.S. A former deputy director of Chi...
For GSK CEO Emma Walmsley, there was good news and bad news in the company’s ann...
Despite falling business interest in environmental, social and governance polici...
Despite falling business interest in environmental, social and governance polici...
On Monday, Delaware’s state investment board approved a $30.2 million grant to M...
As part of a new strategic restructuring to streamline its American operations, ...
With sales of $103 million in the fourth quarter and $180 million in its first n...
With sales of $103 million in the fourth quarter and $180 million in its first n...
On BeiGene’s very first live earnings call, CEO and co-founder John Oyler descri...
After receiving a rare pediatric disease priority review voucher in tandem with ...
Disruptions to government-sanctioned advisory committee meetings on vaccines are...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...